Serial determinations of liver, kidney, spleen, and blood catalase were made on BDF1 mice with leukemia L1210. Total liver catalase was significantly decreased in the terminal stage of the disease. Spleen catalase specific activity was significantly increased in the terminal stage. Kidney and blood catalase were unchanged. In leukemic mice treated with amethopterin, the same changes in catalase occurred, but at a delayed rate. After prolonged therapy, kidney catalase was also depressed.


Supported by grants from USPHS #CA07306-02 and USPHS General Research Support Fund, Graduate School and Institutional Grant from the University of Minnesota and from the American Cancer Society, Minnesota Division.

This content is only available via PDF.